These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
381 related articles for article (PubMed ID: 31214915)
1. Evaluation of EZH2 expression, BRAF V600E mutation, and CDKN2A/B deletions in epithelioid glioblastoma and anaplastic pleomorphic xanthoastrocytoma. Wang J; Liu Z; Cui Y; Liu Y; Fang J; Xu L; He Y; Du J; Su Y; Zou W; Xu Z; Li G J Neurooncol; 2019 Aug; 144(1):137-146. PubMed ID: 31214915 [TBL] [Abstract][Full Text] [Related]
2. Clinicopathological and genetic association between epithelioid glioblastoma and pleomorphic xanthoastrocytoma. Furuta T; Miyoshi H; Komaki S; Arakawa F; Morioka M; Ohshima K; Nakada M; Sugita Y Neuropathology; 2018 Jun; 38(3):218-227. PubMed ID: 29532523 [TBL] [Abstract][Full Text] [Related]
3. BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity. Nakajima N; Nobusawa S; Nakata S; Nakada M; Yamazaki T; Matsumura N; Harada K; Matsuda H; Funata N; Nagai S; Nakamura H; Sasaki A; Akimoto J; Hirato J; Yokoo H Brain Pathol; 2018 Sep; 28(5):663-673. PubMed ID: 29105198 [TBL] [Abstract][Full Text] [Related]
4. Epithelioid Glioblastomas and Anaplastic Epithelioid Pleomorphic Xanthoastrocytomas--Same Entity or First Cousins? Alexandrescu S; Korshunov A; Lai SH; Dabiri S; Patil S; Li R; Shih CS; Bonnin JM; Baker JA; Du E; Scharnhorst DW; Samuel D; Ellison DW; Perry A Brain Pathol; 2016 Mar; 26(2):215-23. PubMed ID: 26238627 [TBL] [Abstract][Full Text] [Related]
5. [Epithelioid glioblastoma with BRAF V600E mutation: a clinicopathological and molecular study]. Zheng LM; Gong J; Zou Y; Zhang MN; Yu TP; Hou J; Zhou Q; Chen N Zhonghua Bing Li Xue Za Zhi; 2021 Mar; 50(3):229-235. PubMed ID: 33677887 [No Abstract] [Full Text] [Related]
6. Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation. Vaubel RA; Caron AA; Yamada S; Decker PA; Eckel Passow JE; Rodriguez FJ; Nageswara Rao AA; Lachance D; Parney I; Jenkins R; Giannini C Brain Pathol; 2018 Mar; 28(2):172-182. PubMed ID: 28181325 [TBL] [Abstract][Full Text] [Related]
7. Clinicopathological characteristics of circumscribed high-grade astrocytomas with an unusual combination of BRAF V600E, ATRX, and CDKN2A/B alternations. Murakami C; Yoshida Y; Yamazaki T; Yamazaki A; Nakata S; Hokama Y; Ishiuchi S; Akimoto J; Shishido-Hara Y; Yoshimoto Y; Matsumura N; Nobusawa S; Ikota H; Yokoo H Brain Tumor Pathol; 2019 Jul; 36(3):103-111. PubMed ID: 30972500 [TBL] [Abstract][Full Text] [Related]
8. BRAF V600E mutation and 9p21: CDKN2A/B and MTAP co-deletions - Markers in the clinical stratification of pediatric gliomas. Frazão L; do Carmo Martins M; Nunes VM; Pimentel J; Faria C; Miguéns J; Sagarribay A; Matos M; Salgado D; Nunes S; Mafra M; Roque L BMC Cancer; 2018 Dec; 18(1):1259. PubMed ID: 30558563 [TBL] [Abstract][Full Text] [Related]
9. Adult epithelioid glioblastoma exhibits an extremely poor prognosis and high frequency of SWI/SNF complex mutation: Insights from a retrospective study. Xi S; Jiang S; Li H; Huang Q; Lu J; Zhang X; Li Z; Zeng J Int J Cancer; 2024 Jul; 155(1):172-183. PubMed ID: 38411299 [TBL] [Abstract][Full Text] [Related]
10. BRAF-mutated pleomorphic xanthoastrocytoma is associated with temporal location, reticulin fiber deposition and CD34 expression. Koelsche C; Sahm F; Wöhrer A; Jeibmann A; Schittenhelm J; Kohlhof P; Preusser M; Romeike B; Dohmen-Scheufler H; Hartmann C; Mittelbronn M; Becker A; von Deimling A; Capper D Brain Pathol; 2014 Apr; 24(3):221-9. PubMed ID: 24345274 [TBL] [Abstract][Full Text] [Related]
11. Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis. Korshunov A; Chavez L; Sharma T; Ryzhova M; Schrimpf D; Stichel D; Capper D; Sturm D; Kool M; Habel A; Kleinschmidt-DeMasters BK; Rosenblum M; Absalyamova O; Golanov A; Lichter P; Pfister SM; Jones DTW; Perry A; von Deimling A Brain Pathol; 2018 Sep; 28(5):656-662. PubMed ID: 28990704 [TBL] [Abstract][Full Text] [Related]
12. Epithelioid glioblastoma arising from pleomorphic xanthoastrocytoma with the BRAF V600E mutation. Tanaka S; Nakada M; Nobusawa S; Suzuki SO; Sabit H; Miyashita K; Hayashi Y Brain Tumor Pathol; 2014 Jul; 31(3):172-6. PubMed ID: 24894018 [TBL] [Abstract][Full Text] [Related]
13. A case of an epithelioid glioblastoma with the BRAF V600E mutation colocalized with BRAF intact low-grade diffuse astrocytoma. Kuroda J; Nobusawa S; Nakamura H; Yokoo H; Ueda R; Makino K; Yano S; Kuratsu J Neuropathology; 2016 Apr; 36(2):181-6. PubMed ID: 26375727 [TBL] [Abstract][Full Text] [Related]
14. BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma. Tabouret E; Bequet C; Denicolaï E; Barrié M; Nanni I; Metellus P; Dufour H; Chinot O; Figarella-Branger D Eur J Surg Oncol; 2015 Dec; 41(12):1685-90. PubMed ID: 26454767 [TBL] [Abstract][Full Text] [Related]
15. Pleomorphic xanthoastrocytoma, anaplastic pleomorphic xanthoastrocytoma, and epithelioid glioblastoma: Case series with clinical characteristics, molecular features and progression relationship. Lin Z; Yang R; Zheng H; Li Z; Yi G; Wu Q; Yang C; Huang G Clin Neurol Neurosurg; 2022 Oct; 221():107379. PubMed ID: 35932588 [TBL] [Abstract][Full Text] [Related]
16. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Schindler G; Capper D; Meyer J; Janzarik W; Omran H; Herold-Mende C; Schmieder K; Wesseling P; Mawrin C; Hasselblatt M; Louis DN; Korshunov A; Pfister S; Hartmann C; Paulus W; Reifenberger G; von Deimling A Acta Neuropathol; 2011 Mar; 121(3):397-405. PubMed ID: 21274720 [TBL] [Abstract][Full Text] [Related]
17. The genetic landscape of anaplastic pleomorphic xanthoastrocytoma. Phillips JJ; Gong H; Chen K; Joseph NM; van Ziffle J; Bastian BC; Grenert JP; Kline CN; Mueller S; Banerjee A; Nicolaides T; Gupta N; Berger MS; Lee HS; Pekmezci M; Tihan T; Bollen AW; Perry A; Shieh JTC; Solomon DA Brain Pathol; 2019 Jan; 29(1):85-96. PubMed ID: 30051528 [TBL] [Abstract][Full Text] [Related]
18. Analysis of 24 cases of epithelioid glioblastoma: Experience from a tertiary centre of North India. Chatterjee D; Radotra BD; Aggarwal D; Madan R; Gupta SK Ann Diagn Pathol; 2021 Feb; 50():151679. PubMed ID: 33341703 [TBL] [Abstract][Full Text] [Related]
19. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. Mistry M; Zhukova N; Merico D; Rakopoulos P; Krishnatry R; Shago M; Stavropoulos J; Alon N; Pole JD; Ray PN; Navickiene V; Mangerel J; Remke M; Buczkowicz P; Ramaswamy V; Guerreiro Stucklin A; Li M; Young EJ; Zhang C; Castelo-Branco P; Bakry D; Laughlin S; Shlien A; Chan J; Ligon KL; Rutka JT; Dirks PB; Taylor MD; Greenberg M; Malkin D; Huang A; Bouffet E; Hawkins CE; Tabori U J Clin Oncol; 2015 Mar; 33(9):1015-22. PubMed ID: 25667294 [TBL] [Abstract][Full Text] [Related]